News and Trends 6 Oct 2016
NASH Maverick continues Rampage with €34M Cash Injection
Genfit just added €34M to its cash pile through private placement to bankroll the development of its succeeding lead candidate, Elafibranor. Genfit has had a good year. Earlier this year, the company enrolled its first patient in Phase III clinical trails for Non-Alcoholic Stato-Hepatitis (NASH), and last month, it launched a new non-invasive diagnostic program. It’s […]
